Medallion Financial Corp. announced that shareholders overwhelmingly re-elected all three of the company's board nominees at the 2026 Annual Meeting, rejecting nominees from activist investor ZimCal Asset Management for the third consecutive year. Shareholder support for Medallion's board averaged about 78%, while support for ZimCal's nominees declined to approximately 19%. This result reinforces shareholder confidence in Medallion's leadership and strategy, which has generated over $375 million in net income before taxes in the last five years and increased dividends by 40% in three years. The company plans to continue focusing on strong financial performance and long-term shareholder value.
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...
The global clinical trials market is projected to grow from $135.51 billion in 2026 to $176.32 billion by 2030, at a CAGR of 6.8%. Growth is fueled by advances in AI-enabled trial design, decentralized and hybrid trial platforms, and increasing deman...
The global hybrid robots market is projected to grow from $5.68 billion in 2026 to $10.03 billion by 2030, with a CAGR of 15.3%. Growth is fueled by advances in AI, autonomous operations, and smart manufacturing, alongside rising demand for robots in...
